What it's for (Indications)
- This sophisticated multi-component medication is primarily indicated for the symptomatic relief of various gastrointestinal disorders associated with hyperacidity, excessive gas, and gastrointestinal spasms.
- These conditions commonly include peptic ulcer disease (for symptomatic management), gastritis, esophagitis, heartburn, and functional dyspepsia.
- Furthermore, it is clinically utilized in the management of irritable bowel syndrome (IBS) to alleviate distressing symptoms such as abdominal pain, cramping, bloating, and flatulence.
- The synergistic action of its components addresses the complex etiology of these conditions, providing comprehensive relief from discomfort, burning sensations, abdominal distention, and painful visceral spasms, thereby improving the patient's quality of life and functional capacity.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The precise dosage regimen for this medicinal combination must always be determined by a qualified healthcare professional, tailored to the individual patient's age, the severity of their symptoms, and their overall clinical response. Typically, for adult patients, the standard oral dosage involves administering 5 to 10 mL (or one to two teaspoonfuls) of the suspension approximately three to four times daily. It is generally recommended to take the dose between meals and at bedtime to maximize efficacy in neutralizing gastric acid and managing nocturnal symptoms. Adherence to the prescribed dosage and frequency is paramount, and patients should be strictly advised against exceeding the maximum recommended daily dose without explicit medical consultation due to the potential for adverse effects and accumulation of active ingredients, especially in patients with compromised renal function or increased sensitivity to anticholinergic effects. |
Safety & Warnings
Common Side Effects
- The administration of this multi-ingredient formulation can lead to a spectrum of adverse reactions, largely attributable to its individual components.
- Common side effects associated with the antacid components (aluminium hydroxide and magnesium hydroxide) include alterations in bowel habits, manifesting as constipation (more prominent with aluminium) or diarrhea (more prominent with magnesium).
- Prolonged or high-dose use of aluminium hydroxide can lead to phosphate depletion, while magnesium hydroxide can precipitate hypermagnesemia in patients with renal impairment.
- Simethicone is generally well-tolerated with minimal systemic absorption, thus rarely causing significant systemic side effects.
- The anticholinergic agent, dicyclomine, is responsible for a wider array of dose-dependent adverse effects such as dry mouth (xerostomia), blurred vision, mydriasis, dizziness, lightheadedness, drowsiness, headache, urinary retention, palpitations, tachycardia, and increased constipation.
- In more sensitive individuals, particularly the elderly, confusion, disorientation, or cognitive impairment may occur.
- Patients should be advised to report any persistent or severe adverse reactions to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: While there is no formal FDA-issued Black Box Warning specifically for this combination product, prescribers and patients must be made aware of significant safety concerns, particularly regarding the dicyclomine component. Serious adverse reactions, including seizures, syncope, apnea, coma, and cardiorespiratory arrest, have been reported in infants treated with dicyclomine. Therefore, this medication is strictly contraindicated in infants younger than 6 months of age. Furthermore, dicyclomine has the potential to induce or exacerbate conditions such as narrow-angle glaucoma, obstructive uropathy (e.g., prostatic hypertrophy), obstructive gastrointestinal disease (e.g., paralytic ileus, severe ulcerative colitis), and myasthenia gravis, for which it is also contraindicated. In elderly patients, anticholinergic effects, such as confusion, hallucinations, and severe constipation or urinary retention, may be more pronounced and require careful monitoring. Healthcare professionals should meticulously evaluate the risk-benefit profile, especially when considering use in vulnerable populations, and ensure that patients are counselled on recognizing and immediately reporting any signs of severe adverse events.
- This medication should be used with extreme caution in several patient populations and clinical scenarios.
- Patients with impaired renal function are at an elevated risk of aluminium and magnesium accumulation, potentially leading to neurotoxicity (aluminium) or hypermagnesemia (magnesium), which can manifest as central nervous system depression, muscle weakness, and cardiac abnormalities.
- Due to the anticholinergic properties of dicyclomine, caution is warranted in patients with pre-existing cardiac conditions, as it can induce or exacerbate tachycardia and other arrhythmias.
- Individuals with narrow-angle glaucoma are contraindicated, and those with prostatic hypertrophy or obstructive uropathy should use it with extreme care due to the risk of exacerbating urinary retention.
- The drug can also impair sweating and heat regulation, predisposing patients to heat prostration, especially during strenuous activity or in hot environments.
- Concomitant use with other medications should be carefully evaluated, as antacids can alter the absorption and bioavailability of numerous drugs by changing gastric pH, and dicyclomine can affect gastrointestinal motility, potentially impacting drug absorption.
- Pediatric and geriatric patients may exhibit increased sensitivity to the anticholinergic effects, necessitating careful dose titration and close monitoring.
How it Works (Mechanism of Action)
The therapeutic efficacy of this combination preparation stems from the synergistic actions of its four distinct pharmacological agents. Aluminium hydroxide and magnesium hydroxide function as direct antacids, neutralizing hydrochloric acid in the gastric lumen. This neutralization elevates gastric pH, which in turn reduces the acidity and inactivates pepsin, an enzyme active in acidic environments, thereby alleviating symptoms of hyperacidity and promoting healing of peptic lesions. Magnesium hydroxide also contributes to a mild osmotic laxative effect at higher doses, counteracting the constipating effect of aluminium. Simethicone, an antiflatulent agent, works by decreasing the surface tension of gas bubbles entrapped in the gastrointestinal tract. This action causes the smaller gas bubbles to coalesce into larger ones, facilitating their easier expulsion via belching or flatus, thus reducing bloating, abdominal distention, and discomfort. Dicyclomine, an antispasmodic and anticholinergic agent, exerts its effects by competitively blocking acetylcholine at muscarinic receptors primarily located on the smooth muscle cells of the gastrointestinal tract. This antagonism leads to a reduction in smooth muscle spasm, decreased gut motility, and inhibition of glandular secretions, thereby effectively alleviating abdominal cramping and pain associated with conditions like irritable bowel syndrome and other spasmodic gastrointestinal conditions.
Commercial Brands (Alternatives)
No other brands found for this formula.